Table 1. Characteristics of 2610 patients followed after initiating 3557 qualifying combination antiretroviral therapy regimens who did and did not develop immune reconstitution inflammatory syndrome in the HIV Outpatient Study, United States, 1996–2007.
| Status during follow-up | ||||
|---|---|---|---|---|
| Baseline characteristic | Total qualifying regimens N = 3557 n (%) |
IRIS N=370 n (%) |
No IRIS N = 3187 n (%) |
P valuea |
| Age (years) | 0.072 | |||
| 18–34 | 859 (24.2) | 104 (28.1) | 755 (23.7) | |
| 35–49 | 2146 (60.3) | 220 (59.5) | 1926 (60.4) | |
| 50+ | 552 (15.5) | 46 (12.4) | 506 (15.9) | |
| Sex | 0.95 | |||
| Female | 726 (20.4) | 76 (20.5) | 650 (20.4) | |
| Male | 2831 (79.6) | 294 (79.5) | 2537 (79.6) | |
| Race/ethnicity | 0.007 | |||
| White, non-Hispanic | 2018 (56.7) | 180 (48.7) | 1838 (57.7) | |
| Black, non-Hispanic | 1051 (29.6) | 127 (34.3) | 924 (29.0) | |
| Hispanic | 374 (10.5) | 51 (13.8) | 323 (10.1) | |
| Other/unknown | 114 (3.2) | 12 (3.2) | 102 (3.2) | |
| HIV transmission risk group | 0.18 | |||
| MSM | 2142 (60.2) | 207 (56.0) | 1935 (60.7) | |
| IDU | 394 (11.1) | 48 (13.0) | 346 (10.9) | |
| Heterosexual | 819 (23.0) | 97 (26.2) | 722 (22.7) | |
| Other/unknown | 202 (5.7) | 18 (4.9) | 184 (5.8) | |
| CD4 cell count category (cells/μl) | <0.001 | |||
| <50 | 557 (16.7) | 137 (41.0) | 420 (14.0) | |
| 50–199 | 905 (27.1) | 93 (27.8) | 812 (27.0) | |
| ≥200 | 1881 (56.3) | 104 (31.1) | 1777 (59.1) | |
| HIV viral load (log10copies/ml) | <0.001 | |||
| <4 | 762 (21.4) | 44 (11.9) | 718 (22.5) | |
| 4-<5 | 1491 (41.9) | 115 (31.1) | 1093 (34.3) | |
| ≥5 | 1304 (36.7) | 211 (57.0) | 1093 (34.3) | |
| HCV co-infection | 0.34 | |||
| Yes | 490 (13.8) | 45 (12.2) | 445 (14.0) | |
| No | 3067 (86.2) | 325 (87.8) | 2742 (86.0) | |
| HBV co-infection | 0.63 | |||
| Yes | 172 (4.8) | 16 (4.3) | 156 (4.9) | |
| No | 3385 (95.2) | 354 (95.7) | 3031 (95.1) | |
| TB exposure | ||||
| Yes | 156 (4.4) | 20 (5.4) | 136 (4.3) | 0.31 |
| No | 3401 (95.6) | 350 (94.6) | 3051 (95.7) | |
HBV, hepatitis B virus;HCV, hepatitis C virus; IRIS, immune reconstitution inflammatory syndrome;TB, tuberculosis.
a
P value determined using the χ2-test.